What is the address of Pharma Bouffioulx?

The registered office of Pharma Bouffioulx is located at Rue Emile Vandervelde 26, 6200 Châtelet.

Is Pharma Bouffioulx still active?

No. The CBE lists Pharma Bouffioulx with legal situation “Opening faillissement”. The date of the court ruling is published in the Belgian Official Gazette; the register does not carry it.

Is Pharma Bouffioulx registered on Peppol?

No, Pharma Bouffioulx is currently not registered on the Peppol network.

What is the enterprise number of Pharma Bouffioulx?

The enterprise number of Pharma Bouffioulx is BE0840730870.

When was Pharma Bouffioulx founded?

Pharma Bouffioulx was founded on 31 October 2011.

Who are the directors of Pharma Bouffioulx?

According to the 2024 annual accounts, the directors of Pharma Bouffioulx are: Sabrina Mastrocristino.

Is Pharma Bouffioulx a reliable company?

Databakkes does not pass judgement; this is what the sources say: Opening faillissement according to the CBE, started on 31 October 2011; 4 annual accounts filed, latest fiscal year 2024; 1 directors known from the annual account.

How much profit did Pharma Bouffioulx make in 2024?

Pharma Bouffioulx recorded a loss after taxes of € 420,375 in financial year 2024.

What is the revenue of Pharma Bouffioulx?

As a small company, Pharma Bouffioulx is not required to publish revenue in its annual accounts. In financial year 2024, its added value was € -6,024.

Pharma Bouffioulx (Private Limited) - Châtelet

Dossier Pharma Bouffioulx, printed on 29 September 2026 from databakkes.be/en/0840730870/pharma-bouffioulx. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 4 of the last 4 fiscal years.
Tight liquidity NBB

Cash and receivables cover 14 % of short-term debt in 2024; threshold 65 %.
Legal situation KBO

Opening faillissement according to the CBE.

Financials

Financial year 2024

Pharma Bouffioulx from Châtelet, company number BE0840730870, closed financial year 2024 with a result of € -420,375 after tax. For that financial year Pharma Bouffioulx recorded a gross margin of € -6,024 and equity of € -482,038. Compared with financial year 2023, the result moved from € 14,215 to € -420,375. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 14, 2025.

What it is worth Caution

€ -482,038

▼ € 420,375 vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -420,375

▼ still € 14,215 profit in 2023

Profit after tax over the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -488,238.

People and assets in 2024

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Debts at end 2024

Bank debt ≈ 7 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 433,016

▼ 9% vs 2023

€ 63,552 is repaid this year. At this pace the long-term loan is gone in ≈ 7 years.

Owed to suppliers

€ 41,749

▼ 2% vs 2023

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 20,998

▼ 14% vs 2023

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2024	Change 2023 → 2024
Gross margin	€ 70,124 Gross margin 2021: € 70,124 First fiscal year in the series	€ 109,210 Gross margin 2022: € 109,210 ▲ 56% vs 2021 (€ 70,124) Favourable step	€ 80,386 Gross margin 2023: € 80,386 ▼ 26% vs 2022 (€ 109,210) Unfavourable step	€ -6,024 Gross margin 2024: € -6,024 ▼ € 86,411 vs 2023 (€ 80,386) Unfavourable step	▼ € 86,411
Profit after taxes	€ -11,526 Profit after taxes 2021: € -11,526 First fiscal year in the series	€ 38,271 Profit after taxes 2022: € 38,271 ▲ € 49,796 vs 2021 (€ -11,526) Favourable step	€ 14,215 Profit after taxes 2023: € 14,215 ▼ 63% vs 2022 (€ 38,271) Unfavourable step	€ -420,375 Profit after taxes 2024: € -420,375 ▼ € 434,590 vs 2023 (€ 14,215) Unfavourable step	▼ € 434,590
Equity	€ -114,148 Equity 2021: € -114,148 First fiscal year in the series	€ -75,877 Equity 2022: € -75,877 ▲ € 38,271 vs 2021 (€ -114,148) Favourable step	€ -61,662 Equity 2023: € -61,662 ▲ € 14,215 vs 2022 (€ -75,877) Favourable step	€ -482,038 Equity 2024: € -482,038 ▼ € 420,375 vs 2023 (€ -61,662) Unfavourable step	▼ € 420,375
Total debts	€ 678,942 Total debts 2021: € 678,942 First fiscal year in the series	€ 597,340 Total debts 2022: € 597,340 ▼ 12% vs 2021 (€ 678,942) Favourable step	€ 556,997 Total debts 2023: € 556,997 ▼ 7% vs 2022 (€ 597,340) Favourable step	€ 500,120 Total debts 2024: € 500,120 ▼ 10% vs 2023 (€ 556,997) Favourable step	▼ 10%
Cash	€ 15,735 Cash 2021: € 15,735 First fiscal year in the series	€ 14,966 Cash 2022: € 14,966 ▼ 5% vs 2021 (€ 15,735) Unfavourable step	€ 4,339 Cash 2023: € 4,339 ▼ 71% vs 2022 (€ 14,966) Unfavourable step	-
Retained profit	€ -120,348 Retained profit 2021: € -120,348 First fiscal year in the series	€ -82,077 Retained profit 2022: € -82,077 ▲ € 38,271 vs 2021 (€ -120,348) Favourable step	€ -67,862 Retained profit 2023: € -67,862 ▲ € 14,215 vs 2022 (€ -82,077) Favourable step	€ -488,238 Retained profit 2024: € -488,238 ▼ € 420,375 vs 2023 (€ -67,862) Unfavourable step	▼ € 420,375
Bank debt	€ 559,467 Bank debt 2021: € 559,467 First fiscal year in the series	€ 514,730 Bank debt 2022: € 514,730 ▼ 8% vs 2021 (€ 559,467) Favourable step	€ 477,110 Bank debt 2023: € 477,110 ▼ 7% vs 2022 (€ 514,730) Favourable step	€ 433,016 Bank debt 2024: € 433,016 ▼ 9% vs 2023 (€ 477,110) Favourable step	▼ 9%
Balance sheet total	€ 564,794 Balance sheet total 2021: € 564,794 First fiscal year in the series	€ 521,463 Balance sheet total 2022: € 521,463 ▼ 8% vs 2021 (€ 564,794) Unchanged	€ 495,335 Balance sheet total 2023: € 495,335 ▼ 5% vs 2022 (€ 521,463) Unchanged	€ 18,082 Balance sheet total 2024: € 18,082 ▼ 96% vs 2023 (€ 495,335) Unchanged	▼ 96%

Key figures of Pharma Bouffioulx, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to Pharma Bouffioulx?

What happened at Pharma Bouffioulx in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Pharma Bouffioulx is active according to the CBE. Legal situation: Opening faillissement.

Aug 14, 2025 New annual accounts for financial year 2024: loss of € 420,375 (▼ € 434,590 vs 2023). filed late Source: NBB ↗
2011 Sabrina Mastrocristino became a director. NBB
Oct 31, 2011 Start of the company according to the CBE. KBO

In short

From € 11,526 loss in 2021 to € 420,375 loss in 2024.

Paid € 40,702 in corporate taxes since 2021.

Best year ever: 2022, with € 38,271 profit.

Original PDFs at the National Bank ↗

A new publication or filing at Pharma Bouffioulx? We notify you, reason included.

Follow Pharma Bouffioulx

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Sabrina Mastrocristino

Pharma Bouffioulx

Behind Pharma Bouffioulx is Sabrina Mastrocristino.

See the full network in the app

Directors

According to the 2024 annual accounts

Sabrina Mastrocristino

Director

since 2011

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Emile Vandervelde 26

6200 Châtelet

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0840.730.870
VAT number: BE 0840.730.870
Registered office: Rue Emile Vandervelde 26, 6200 Châtelet
Names & denominations: Pharma Bouffioulx
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Opening faillissement
Start date: 31 October 2011
Peppol: Not registered

View on CBE Public ↗ Annual accounts (NBB) ↗